share_log

Stryker Co. (NYSE:SYK) Shares Purchased by Tectonic Advisors LLC

Stryker Co. (NYSE:SYK) Shares Purchased by Tectonic Advisors LLC

Stryker Co.纽约证券交易所代码:SYK)Tectonic Advisors LLC 收购的股票
Financial News Live ·  2023/02/02 17:12

Tectonic Advisors LLC increased its position in shares of Stryker Co. (NYSE:SYK – Get Rating) by 16.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,503 shares of the medical technology company's stock after purchasing an additional 215 shares during the quarter. Tectonic Advisors LLC's holdings in Stryker were worth $304,000 as of its most recent SEC filing.

Structure Advisors LLC最近提交给美国证券交易委员会(Securities&Exchange Commission)的Form 13F文件显示,该公司第三季度将Stryker Co.(NYSE:SYK-GET评级)的股票头寸增加了16.7%。该公司在本季度额外购买了215股后,拥有1,503股这家医疗技术公司的股票。截至最近提交给美国证券交易委员会的文件,Structure Advisors LLC持有的Stryker股份价值30.4万美元。

A number of other institutional investors and hedge funds have also recently modified their holdings of SYK. Ontario Teachers Pension Plan Board lifted its holdings in shares of Stryker by 87,902.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 2,077,732 shares of the medical technology company's stock worth $555,482,000 after purchasing an additional 2,075,371 shares during the period. Clearbridge Investments LLC lifted its holdings in Stryker by 664.0% in the second quarter. Clearbridge Investments LLC now owns 2,199,253 shares of the medical technology company's stock valued at $437,497,000 after acquiring an additional 1,911,376 shares during the period. TD Asset Management Inc. lifted its holdings in Stryker by 76.6% in the second quarter. TD Asset Management Inc. now owns 1,364,821 shares of the medical technology company's stock valued at $271,504,000 after acquiring an additional 592,179 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in Stryker by 126.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 694,478 shares of the medical technology company's stock valued at $185,669,000 after acquiring an additional 388,467 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Stryker by 17.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,437,580 shares of the medical technology company's stock valued at $384,336,000 after acquiring an additional 213,582 shares during the period. Institutional investors and hedge funds own 77.10% of the company's stock.

其他一些机构投资者和对冲基金最近也调整了对SYK的持股。安大略省教师养老金计划委员会在第一季度增持了87,902.2%的Stryker股票。安大略省教师养老金计划委员会现在拥有这家医疗技术公司的2,077,732股股票,价值555,482,000美元,在此期间额外购买了2,075,371股票。ClearBridge Investments LLC在第二季度增持了664.0%的Stryker股份。ClearBridge Investments LLC现在拥有这家医疗技术公司2,199,253股股票,价值437,497,000美元,在此期间又购买了1,911,376股。道明资产管理公司在第二季度增持了76.6%的Stryker股份。TD Asset Management Inc.在此期间增持了592,179股,目前持有这家医疗技术公司1,364,821股股票,价值271,504,000美元。ArrowStreet Capital Limited Partnership在第一季度增持了126.9%的Stryker股份。ArrowStreet Capital Limited Partnership现在拥有这家医疗技术公司694,478股股票,价值185,669,000美元,在此期间又购买了388,467股。最后,高盛股份有限公司在第一季度增持了史赛克17.4%的股份。高盛股份有限公司在此期间增持了213,582股,目前持有这家医疗技术公司1,437,580股股票,价值384,336,000美元。机构投资者和对冲基金持有该公司77.10%的股票。

Get
到达
Stryker
史崔克
alerts:
警报:

Insider Activity

内幕活动

In related news, VP M Kathryn Fink sold 6,571 shares of the firm's stock in a transaction that occurred on Wednesday, January 11th. The stock was sold at an average price of $257.69, for a total transaction of $1,693,280.99. Following the transaction, the vice president now owns 9,264 shares in the company, valued at approximately $2,387,240.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Srikant M. Datar sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 7th. The stock was sold at an average price of $240.25, for a total transaction of $240,250.00. Following the transaction, the director now owns 6,262 shares in the company, valued at approximately $1,504,445.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP M Kathryn Fink sold 6,571 shares of the stock in a transaction that occurred on Wednesday, January 11th. The stock was sold at an average price of $257.69, for a total value of $1,693,280.99. Following the sale, the vice president now directly owns 9,264 shares of the company's stock, valued at $2,387,240.16. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 79,139 shares of company stock worth $19,150,115. 6.70% of the stock is currently owned by insiders.

在相关新闻中,副总裁凯瑟琳·芬克在1月11日星期三的一次交易中出售了6571股该公司的股票。股票以257.69美元的平均价格出售,总成交金额为1,693,280.99美元。交易完成后,副总经理总裁现在拥有该公司9264股,价值约2387,240.16美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在这个环节。在相关新闻中,董事在12月7日星期三的一次交易中出售了1,000股该公司的股票。该股以240.25美元的平均价格出售,总成交金额为240,250.00美元。交易完成后,董事现在拥有该公司6,262股股份,价值约1,504,445.50美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在这个环节。此外,副总裁M凯瑟琳·芬克在1月11日星期三的一笔交易中出售了6571股该股。这只股票的平均售价为257.69美元,总价值为1,693,280.99美元。出售股份后,总裁副手现在直接持有该公司9264股股票,价值2387,240.16美元。关于这次销售的披露可以找到这里。在过去的90天里,内部人士出售了79,139股公司股票,价值19,150,115美元。该公司6.70%的股份目前由内部人士持有。

Stryker Price Performance

Stryker价格表现

Shares of NYSE SYK opened at $280.70 on Thursday. Stryker Co. has a 1-year low of $188.84 and a 1-year high of $281.45. The company has a market cap of $106.23 billion, a price-to-earnings ratio of 45.21, a price-to-earnings-growth ratio of 2.83 and a beta of 0.93. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.04 and a quick ratio of 1.19. The stock's 50-day moving average is $246.81 and its two-hundred day moving average is $225.74.
纽约证交所SYK股价周四开盘报280.70美元。Stryker Co.的股价为一年低点188.84美元,一年高点为281.45美元。该公司市值为1,062.3亿美元,市盈率为45.21倍,市盈率为2.83倍,贝塔系数为0.93。该公司的债务权益比为0.77,流动比率为2.04,速动比率为1.19。该股的50日移动均线切入位在246.81美元,200日移动均线切入位在225.74美元。

Stryker (NYSE:SYK – Get Rating) last released its quarterly earnings data on Tuesday, January 31st. The medical technology company reported $3.00 EPS for the quarter, beating analysts' consensus estimates of $2.84 by $0.16. Stryker had a return on equity of 22.70% and a net margin of 12.78%. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the prior year, the business posted $2.71 EPS. The business's revenue for the quarter was up 10.7% on a year-over-year basis. Analysts forecast that Stryker Co. will post 9.83 EPS for the current fiscal year.

Stryker(纽约证券交易所代码:SYK-GET Rating)最近一次发布季度收益数据是在1月31日星期二。这家医疗技术公司公布本季度每股收益为3.00美元,比分析师普遍预期的2.84美元高出0.16美元。Stryker的股本回报率为22.70%,净利润率为12.78%。该业务本季度营收为52亿美元,而市场普遍预期为49.7亿美元。在去年同一季度,该业务公布的每股收益为2.71美元。该业务当季营收较上年同期增长10.7%。分析师预计,Stryker Co.本财年每股收益将达到9.83欧元。

Stryker Increases Dividend

Stryker增加股息

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, January 31st. Stockholders of record on Friday, December 30th were issued a $0.75 dividend. The ex-dividend date of this dividend was Thursday, December 29th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.07%. This is an increase from Stryker's previous quarterly dividend of $0.70. Stryker's dividend payout ratio is presently 48.62%.

该公司最近还披露了季度股息,股息于1月31日(星期二)支付。12月30日星期五,登记在册的股东获得了0.75美元的股息。本次股息除息日期为12月29日星期四。这意味着年化股息为3.00美元,股息收益率为1.07%。这比Stryker之前0.70美元的季度股息有所增加。Stryker的股息支付率目前为48.62%。

Wall Street Analysts Forecast Growth

华尔街分析师预测经济增长

SYK has been the subject of a number of recent analyst reports. Cowen boosted their price objective on Stryker from $233.00 to $283.00 in a research report on Wednesday, December 14th. Evercore ISI boosted their price target on Stryker to $265.00 in a research report on Tuesday, January 3rd. Canaccord Genuity Group boosted their price target on Stryker from $220.00 to $250.00 and gave the stock a "hold" rating in a research report on Wednesday. Robert W. Baird boosted their price target on Stryker from $240.00 to $287.00 and gave the stock an "outperform" rating in a research report on Wednesday. Finally, Loop Capital upped their target price on Stryker from $245.00 to $290.00 and gave the company a "buy" rating in a report on Wednesday. Seven research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and a consensus price target of $271.32.

SYK是最近多份分析师报告的主题。考恩在12月14日星期三的一份研究报告中将他们对Stryker的目标价从233.00美元上调至283.00美元。1月3日,Evercore ISI在一份研究报告中将他们对Stryker的目标价上调至265.00美元。在周三的一份研究报告中,Cancord Genuity Group将Stryker的目标价从220.00美元上调至250.00美元,并给予该股“持有”评级。周三,罗伯特·W·贝尔德在一份研究报告中将Stryker的目标价从240.00美元上调至287.00美元,并给予该股“跑赢大盘”的评级。最后,Loop Capital在周三的一份报告中将Stryker的目标价从245.00美元上调至290.00美元,并给予该公司“买入”评级。7名研究分析师对该股的评级为持有,14名分析师对该股的评级为买入。根据MarketBeat的数据,Stryker目前的共识评级为“适度买入”,共识目标价为271.32美元。

Stryker Company Profile

Stryker公司简介

(Get Rating)

(获取评级)

Stryker Corp. operates as a medical technology company. It operates through the following segments: Orthopaedics & Spine and MedSurg & Neurotechnology. The Orthopaedics & Spine segment provides implants for use in total joint replacements, such as hip, knee, and shoulder, and trauma and extremities surgeries.

Stryker Corp.是一家医疗技术公司。它通过以下部门开展业务:整形外科和脊柱以及医学外科和神经技术。骨科和脊柱部门提供用于全关节置换的植入物,如髋关节、膝盖和肩部,以及创伤和四肢手术。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on Stryker (SYK)
  • The Bottom Is In For Meta Platforms, Volatility Is Not Over
  • Analyzing Alaska Air's Recent Earnings
  • Apple's Earnings, Expectations and Surprises
  • T-Mobile Delivers Where it Matters Most to Investors
  • Exxon Mobil Could Gush To New Highs Very Soon
  • 免费获取StockNews.com关于Stryker的研究报告(SYK)
  • Meta平台的底部已经到了,波动性还没有结束
  • 阿拉斯加航空公司近期收益分析
  • 苹果的收益、预期和惊喜
  • T-Mobile在对投资者最重要的领域提供服务
  • 埃克森美孚可能很快创下新高

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

接受Stryker Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Stryker和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发